文献速递骨软组织肉瘤与黑色素瘤

美法仑隔离肝灌注治疗孤立性葡萄膜黑色素瘤肝转移患者:一项多中心、随机、开放标签、III期试验(SCANDIUM试验)

Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial).
PubMed 文献 · J Clin Oncol · 2023-03-20

这项多中心、随机、开放标签、III期试验将既往未治疗的孤立性葡萄膜黑色素瘤肝转移患者随机分配至一次性美法仑隔离肝灌注(IHP)组或最佳替代治疗对照组。意向性分析显示,IHP组与对照组的客观缓解率分别为40%与4.5%(P<.0001),中位无进展生存期分别为7.4个月与3.3个月(P<.0001,HR 0.21,95%CI 0.12-0.36),中位肝脏无进展生存期分别为9.1个月与3.3个月(P<.0001),均 favoring IHP组。IHP组治疗相关严重不良事件11例,对照组7例,IHP组有1例治疗相关死亡。

要点

  • IHP组客观缓解率40%,对照组4.5%(P<.0001)。
  • IHP组中位PFS 7.4个月,对照组3.3个月(HR 0.21,95%CI 0.12-0.36)。
  • IHP组治疗相关严重不良事件11例,对照组7例,IHP组有1例治疗相关死亡。

核心结论

  • 在既往未治疗的孤立性葡萄膜黑色素瘤肝转移患者中,与最佳替代治疗相比,美法仑隔离肝灌注获得了更优的客观缓解率、肝脏无进展生存期和无进展生存期。

研究设计与样本

  • 多中心、随机、开放标签、III期试验,纳入既往未治疗的孤立性葡萄膜黑色素瘤肝转移患者。
  • 共93例患者随机分组,87例分配至IHP组(n=43)或对照组(n=44),对照组接受研究者选择的治疗。
  • 对照组中49%接受化疗,39%接受免疫检查点抑制剂,9%接受除IHP以外的局部区域治疗。

主要发现

  • 意向性分析中,IHP组与对照组的客观缓解率分别为40%与4.5%(P<.0001)。
  • IHP组与对照组的中位无进展生存期分别为7.4个月与3.3个月(P<.0001),风险比为0.21(95%CI,0.12至0.36)。
  • IHP组与对照组的中位肝脏无进展生存期分别为9.1个月与3.3个月(P<.0001)。
  • IHP组治疗相关严重不良事件11例,对照组7例;IHP组有1例治疗相关死亡。

关键数值与推荐

  • 客观缓解率按RECIST 1.1标准评估,IHP组40% vs 对照组4.5%(P<.0001)。
  • 中位无进展生存期IHP组7.4个月 vs 对照组3.3个月(P<.0001),HR 0.21(95%CI 0.12-0.36)。
  • 中位肝脏无进展生存期IHP组9.1个月 vs 对照组3.3个月(P<.0001)。
  • 治疗相关严重不良事件:IHP组11例 vs 对照组7例;治疗相关死亡:IHP组1例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: About half of patients with metastatic uveal melanoma present with isolated liver metastasis, in whom the median survival is 6-12 months. The few systemic treatment options available only moderately prolong survival. Isolated hepatic perfusion (IHP) with melphalan is a regional treatment option, but prospective efficacy and safety data are lacking. METHODS: In this multicenter, randomized, open-label, phase III trial, patients with previously untreated isolated liver metastases from uveal melanoma were randomly assigned to receive a one-time treatment with IHP with melphalan or best alternative care (control group). The primary end point was overall survival at 24 months. Here, we report the secondary outcomes of response according to RECIST 1.1 criteria, progression-free survival (PFS), hepatic PFS (hPFS), and safety. RESULTS: Ninety-three patients were randomly assigned, and 87 patients were assigned to either IHP (n = 43) or a control group receiving the investigator's choice of treatment (n = 44). In the control group, 49% received chemotherapy, 39% immune checkpoint inhibitors, and 9% locoregional treatment other than IHP. In an intention-to-treat analysis, the overall response rates (ORRs) were 40% versus 4.5% in the IHP and control groups, respectively (P < .0001). The median PFS was 7.4 months versus 3.3 months (P < .0001), with a hazard ratio of 0.21 (95% CI, 0.12 to 0.36), and the median hPFS was 9.1 months versus 3.3 months (P < .0001), both favoring the IHP arm. There were 11 treatment-related serious adverse events in the IHP group compared with seven in the control group. There was one treatment-related death in the IHP group. CONCLUSION: IHP treatment resulted in superior ORR, hPFS, and PFS compared with best alternative care in previously untreated patients with isolated liver metastases from primary uveal melanoma.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Olofsson Bagge R, Nelson A, Shafazand A, et al. Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial). J Clin Oncol. 2023. PMID: 36940407. doi:10.1200/JCO.22.01705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。